Icatibant Medical Valley (Icatibant)

Icatibant is a selective competitive antagonist of the bradykinin B2 receptor. By binding to this receptor, it blocks the action of bradykinin, a peptide that causes vasodilation and increased vascular permeability. This inhibition prevents the swelling characteristic of hereditary angioedema and leads to quick symptom relief.

The prescribed dose of icatibant is determined by the treating physician. In clinical practice, a single subcutaneous injection of 30 mg is commonly used for an acute HAE attack, and a second dose may be administered after at least six hours if needed. Exact dosing and repeat‑treatment intervals should follow the prescriber's instructions.

Safety data for icatibant in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers should discuss individual circumstances with the patient and consider alternative therapies if appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

The primary alternative for acute HAE attacks is plasma‑derived or recombinant C1‑esterase inhibitor concentrates. While both classes provide rapid symptom control, icatibant works by blocking the bradykinin B2 receptor, whereas C1‑esterase inhibitors replace the deficient protein. Icatibant is administered subcutaneously and may be preferred when intravenous access is limited, but individual response and safety profiles guide therapy choice.

Icatibant should be stored at 2 °C to 8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 °C for a short period, then return to refrigeration as soon as possible.

Icatibant is given as a subcutaneous injection, typically into the abdomen, thigh, or upper arm. The injection site should be rotated for repeated doses to minimize local irritation. Administration is performed by a trained healthcare professional or, in some cases, by the patient after appropriate instruction.

The most serious adverse events include anaphylactic reactions, severe angioedema of the face or airway, and sudden hypotension. Patients should be monitored closely after the first injection, and any signs of severe allergic response or breathing difficulty require immediate medical attention.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients with unstable cardiovascular disease, those taking ACE inhibitors without proper monitoring, and pregnant or breastfeeding women unless the potential benefit outweighs the risk.